Research and Development
Weekly Movers: Lion Biotech, Adamis, Sarepta…
June 13, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Alexion, Biogen, Shares, Stock Markets, Stock Movement, drug trial, sarepta
Novo Nordisk presents Tresiba data showing significantly lower hypoglycaemia rates
June 13, 2016 Research and Development, Sales and Marketing Novo Nordisk, Tresiba
Google’s DeepMind to apply artificial intelligence technology to NHS in next five years
June 13, 2016 Medical Communications, Research and Development, Sales and Marketing DeepMind, NHS, collaboration, google, health tech
Pfizer’s leukaemia drug beats chemotherapy in Phase III trials
June 13, 2016 Research and Development, Sales and Marketing Inotuzumab ozogamicin, Pfizer, acute lymphoblastic leukaemia
Shares in Global Blood jump after positive results for trial sickle cell drug
June 13, 2016 Research and Development, Sales and Marketing Global Blood Therapeutics, drug trial, sickle cell disease
EU ombudsman calls for more transparency from AbbVie on Humira
June 10, 2016 Medical Communications, Research and Development AbbVie, EMA, EU, Humira, ombudsman
Boehringer Ingelheim names Simone Menne new chief financial officer
June 10, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim
New high-risk treatment can halt MS, claim researchers
June 10, 2016 Research and Development multiple sclerosis, research
FDA committee recommends MSD’s c. diff prevention drug
June 10, 2016 Medical Communications, Research and Development, Sales and Marketing FDA, MSD, Merck, bezlotoxumab, committee, zinplava
Novartis presents strong results in rare blood disorder trials
June 10, 2016 Medical Communications, Research and Development Jakavi, Novartis, Revolade, blood disorder
Janssen says its immunotherapy daratumumab extends progression-free survival in combination study to treat multiple myeloma
June 10, 2016 Medical Communications, Research and Development Janssen, Phase III trials, drug trial, immunotherapy, multiple myeloma
Nice says Bayer’s Eylea not recommended as first-line treatment in draft recommendation
June 10, 2016 Medical Communications, Research and Development Bayer, Eylea, NICE, recommendation, regulation
Amgen, Novartis migraine drug meets primary endpoint in Phase II study
June 9, 2016 Research and Development AMG 334, Amgen, Novartis, Phase II, chronic, erenumab, migraine
GSK, Janssen RA treatment meets co-primary endpoints in Phase III trial
June 9, 2016 Research and Development GSK, Janssen, eular 2016, rheumatoid arthritis, sirukumab
Sandoz biosimilars as safe and efficacious as originators, says early trials data
June 9, 2016 Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab
